Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Aditxt has completed all preclinical studies on its lead therapeutic candidate ADI‑100 with positive safety and efficacy data in autoimmune models including type I diabetes and psoriasis. The company’s diagnostic programs are commercially available or near-commercialization. First-in-human clinical trials are planned or underway in Germany and the U.S., targeting autoimmune diseases such as psoriasis, T1D, and Stiff Person Syndrome.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Aditxt, Inc..